<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361487</url>
  </required_header>
  <id_info>
    <org_study_id>NOVOSTITCH.2019.09</org_study_id>
    <nct_id>NCT04361487</nct_id>
  </id_info>
  <brief_title>Circumferential Compression STITCH Repairs of Complex and Horizontal Cleavage Meniscal Tears</brief_title>
  <acronym>NOVOSTITCH PRO</acronym>
  <official_title>Circumferential Compression STITCH Repairs of Complex and Horizontal Cleavage Meniscal Tears</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith &amp; Nephew, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smith &amp; Nephew, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand the benefits and safety of the NOVOSTITCH PRO&#xD;
      Meniscal Repair (NOVOSTITCH PRO) system. The meniscus is a tissue in the knee joint. The&#xD;
      NOVOSTITCH PRO is used during surgery to fix meniscus tears in the knee. It is unknown&#xD;
      whether fixing a meniscus tear is better than the approach of removing the tear. Data will be&#xD;
      collected on participants prior to surgery, at surgery, and for 2 years after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to understand the benefits and safety of the NOVOSTITCH PRO&#xD;
      Meniscal Repair (NOVOSTITCH PRO) system. The meniscus is a tissue in the knee joint. The&#xD;
      NOVOSTITCH PRO is used during surgery to fix meniscus tears in the knee. It is unknown&#xD;
      whether fixing a meniscus tear is better than the approach of removing the tear. Data will be&#xD;
      collected on participants prior to surgery, at surgery, and for 2 years after surgery.&#xD;
&#xD;
      There are different types of tears in the meniscus. This study includes 2 of the tear types:&#xD;
      horizontal cleavage and complex meniscal tears.&#xD;
&#xD;
      Participants will be consented and enrolled in the study prior to knee surgery. Participants&#xD;
      will complete surveys before surgery and data obtained from the medical record. In addition,&#xD;
      standard of care x-rays and MRIs of the knee will be sent to the study. Participants will&#xD;
      have their standard of care surgery to repair the knee using NOVOSTITCH PRO. Images and&#xD;
      videos inside the knee during surgery may be sent to the study.&#xD;
&#xD;
      Participants will be followed 2 years after surgery. There are a total of 5 follow-up visits:&#xD;
      2 weeks, 3 months, 6 months, 1 year, and 2 years after surgery. Data will be obtained from&#xD;
      medical records, surveys, MRIs, and radiographs. Up to 30 participants will have an optional&#xD;
      needle endoscopy at the 6-month follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of reoperation due to meniscal repair failure at 12 months after surgery</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of reoperation due to meniscal repair failure at 6 months after surgery</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of reoperation due to meniscal repair failure at 24 months after surgery</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural integrity of meniscus assessed by MRI</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tibiofemoral joint space narrowing assessed by x-ray</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing status assessed by in-office needle endoscopy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome (PRO): International Knee Documentation Committee (IKDC) Subjective ScoreOutcomes scores</measure>
    <time_frame>6, 12, and 24 months</time_frame>
    <description>The International Knee Documentation Committee (IKDC) Subjective score was developed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment, including patients with meniscal injuries.&#xD;
There are three domains: 1) symptoms, including pain, stiffness, swelling, locking/catching, and giving way (7 items), 2) sports and daily activities (10 items), and 3) current knee function and knee function prior to knee injury (1 item, not included in the score). Responses vary for each item. The possible score ranges from 0-100, where 100 = no limitation with daily or sporting activities and the absence of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome (PRO): Knee Injury and Osteoarthritis Outcome Score (KOOS) Outcomes scores</measure>
    <time_frame>6, 12, and 24 months</time_frame>
    <description>There are five patient-relevant subscales of the KOOS, and each are scored separately:&#xD;
Pain (9 items), Symptoms (7 items), ADL function (17 items), Sport and Recreation Function (5 items), and Quality of Life (4 items).&#xD;
A Likert scale is used and all items have five possible answer options scored from 0 (no problems) to 4 (extreme problems). Each of the 5 scores is calculated as the sum of the items included and then each score is transformed to a 0-100 scale, with 0 representing extreme knee problems and 100 representing no knee problems as common in orthopedic assessment scales and generic measures. An aggregate score is not calculated so that each of the 5 dimensions can be assess separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome (PRO):LysholmOutcomes scores</measure>
    <time_frame>6, 12, and 24 months</time_frame>
    <description>This tool measures the domains of symptoms and complaints and functioning of daily activities. The scale consists of 8 item and is scaled from 0 to 100, with a higher score indicating fewer symptoms and higher level of functioning.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Meniscus Tear</condition>
  <condition>Retention; Meniscus</condition>
  <arm_group>
    <arm_group_label>Horizontal Cleavage Meniscal Tear</arm_group_label>
    <description>Participants with horizontal cleavage meniscal tears</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Complex Meniscal Tear</arm_group_label>
    <description>Participants with complex meniscal tears</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NOVOSTITCH PRO Meniscal Repair System</intervention_name>
    <description>Standard of care surgery with in which the meniscus is repaired using NOVOSTITCH PRO</description>
    <arm_group_label>Complex Meniscal Tear</arm_group_label>
    <arm_group_label>Horizontal Cleavage Meniscal Tear</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited at the sports medicine/orthopedic clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects will be eligible for the study if they meet all of the following criteria at&#xD;
             the Baseline Screening:&#xD;
&#xD;
               1. Able and willing to give informed consent by voluntarily providing written&#xD;
                  informed consent in accordance with governing Institutional Review Board;&#xD;
&#xD;
               2. 18 to 70 years of age, inclusive at the time of screening;&#xD;
&#xD;
               3. History indicative of meniscal pathology (e.g., pain, mechanical symptoms&#xD;
                  described as locking, clicking or giving way);&#xD;
&#xD;
               4. Physical exam consistent with meniscus tear (e.g., locked joint, joint line&#xD;
                  tenderness and/or pain on meniscal compression);&#xD;
&#xD;
               5. If prior ligament reconstruction, the study knee is clinically stable;&#xD;
&#xD;
               6. Meniscal repair to be performed arthroscopically;&#xD;
&#xD;
               7. Preoperative MRI evidence consistent with a horizontal cleavage or complex&#xD;
                  meniscus tear in the symptomatic compartment;&#xD;
&#xD;
               8. Willing and able to comply with all study procedures and visit requirements,&#xD;
                  including MRIs, X-rays, and Case Report Forms (CRFs) completed by the subject.&#xD;
&#xD;
          -  Consented subjects may be included in the study only if, upon arthroscopic inspection&#xD;
             during the procedure, their meniscal study lesion meets all of the following criteria:&#xD;
&#xD;
               1. Meniscal tear amenable to repair with NOVOSTITCH PRO with or without the use of&#xD;
                  adjunct devices per the exclusion criteria;&#xD;
&#xD;
               2. Tear pattern is one of the following:&#xD;
&#xD;
                    1. Horizontal cleavage tear (HCT), or&#xD;
&#xD;
                    2. Complex multi-planar tear (combination of at least two of the following&#xD;
                       tears: horizontal, oblique, radial, vertical).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects will be excluded from the study if they meet any of following criteria at the&#xD;
             Baseline Screening:&#xD;
&#xD;
               1. Arthritis in the study knee (Kellgren-Lawrence Grade 3 or higher);&#xD;
&#xD;
               2. Body Mass Index (BMI) â‰¥40 kg/m2;&#xD;
&#xD;
               3. Previous surgical meniscal repair or meniscectomy of the study meniscus;&#xD;
&#xD;
               4. Unstable knee;&#xD;
&#xD;
               5. Clinically significant malalignment of the study knee, and/or requiring&#xD;
                  osteotomy, and/or correction;&#xD;
&#xD;
               6. History of constitutional/systemic inflammatory/arthritic problem or pain&#xD;
                  condition, history of knee infection, vascular condition of legs, benign&#xD;
                  neoplasms of knee, hepatitis, and/or HIV;&#xD;
&#xD;
               7. Currently on any immunosuppressive therapy;&#xD;
&#xD;
               8. Expected to undergo any other surgical treatment of either knee;&#xD;
&#xD;
               9. Previously enrolled in the study (no bilateral knee surgeries);&#xD;
&#xD;
              10. Surgical procedures other than those listed in the Indications for Use;&#xD;
&#xD;
              11. Patient conditions including insufficient quantity or quality of tissue;&#xD;
&#xD;
              12. Insufficient blood supply or previous infections which may hinder the healing&#xD;
                  process;&#xD;
&#xD;
              13. Foreign body sensitivity. If material sensitivity is suspected, testing should be&#xD;
                  completed prior to suture implantation;&#xD;
&#xD;
              14. Conditions which may limit the patient's ability or willingness to follow&#xD;
                  postoperative care instructions;&#xD;
&#xD;
              15. Any concomitant painful or disabling disease, condition or post-procedure status&#xD;
                  of either lower extremity that would interfere with evaluation or rehabilitation&#xD;
                  of the study knee;&#xD;
&#xD;
              16. Pregnant or planning to become pregnant in the next 2 years;&#xD;
&#xD;
              17. Subject does not understand a language in which the PROs and EQ-5D-5L are&#xD;
                  available.&#xD;
&#xD;
          -  Subjects will be excluded from the study if their study meniscus lesion meets any of&#xD;
             the following criteria at arthroscopy:&#xD;
&#xD;
               1. Ramp tears;&#xD;
&#xD;
               2. Root or other tear type requiring tibial fixation;&#xD;
&#xD;
               3. Tears requiring repair of both meniscus in the study knee;&#xD;
&#xD;
               4. Intact or partially intact meniscus tear that, in the opinion of the&#xD;
                  Investigator, does not require repair;&#xD;
&#xD;
               5. Poor meniscal tissue quality such that it will not hold a suture;&#xD;
&#xD;
               6. For HCTs:&#xD;
&#xD;
                    1. Use of any capsular fixation device; OR&#xD;
&#xD;
                    2. Any portion of the meniscal tear is repaired using a device to place&#xD;
                       stitches other than NOVOSTITCH PRO, Meniscus Mender II, or Meniscal&#xD;
                       Stitcher, or FIRSTPASS MINI marketed by Smith + Nephew Inc.;&#xD;
&#xD;
               7. For complex tears:&#xD;
&#xD;
                  a. Any portion of the meniscal tear is repaired using a device to place stitches&#xD;
                  other than NOVOSTITCH PRO, Meniscus Mender II, Meniscal Stitcher, FIRSTPASS MINI,&#xD;
                  FAST-FIX 360, or ULTRA FAST-FIX marketed by Smith + Nephew Inc.;&#xD;
&#xD;
               8. Clinically significant (zone 1 and/or zone 2) tear in the contralateral&#xD;
                  compartment to the study meniscus;&#xD;
&#xD;
               9. Performance of a significant concomitant procedure (e.g. ACL reconstruction or&#xD;
                  repair, cartilage repair or restoration) intended as a therapeutic intervention&#xD;
                  on the study knee;&#xD;
&#xD;
              10. Presence of infection;&#xD;
&#xD;
              11. Articular cartilage damage in the study knee, defined as Modified Outerbridge&#xD;
                  Grade III or higher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darvin Griffin, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Smith &amp; Nephew, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharron McCulloch, MS</last_name>
    <role>Study Director</role>
    <affiliation>Smith &amp; Nephew, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roxanne Sumner</last_name>
    <phone>9198576440</phone>
    <email>Roxanne.Sumner@smith-nephew.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karlie Morgan</last_name>
    <phone>512-496-7507</phone>
    <email>karlie.morgan@smith-nephew.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CAO Research Foundation</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Tam, CPHT</last_name>
      <phone>202-256-9353</phone>
      <email>stacy.tam@caoresearch.org</email>
    </contact>
    <investigator>
      <last_name>Scott Faucett, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hawai'i Pacific Health / Straub Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Andrews, PhD, ATC</last_name>
      <phone>808-522-4822</phone>
      <email>samantha.andrews@straub.net</email>
    </contact>
    <investigator>
      <last_name>Spencer Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center / Midwest Orthopaedics at Rush</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kavita Ahuja</last_name>
      <phone>224-229-2988</phone>
      <email>kavita.ahuja@rushortho.com</email>
    </contact>
    <investigator>
      <last_name>Jorge Chahla, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin Tarakemeh</last_name>
      <phone>913-956-2100</phone>
      <email>atarakemeh@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Bradshaw</last_name>
      <phone>913-256-2100</phone>
      <email>sbradshaw2@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Paul Schroeppel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott Mullen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bryan Vopat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciara Terry</last_name>
      <phone>507-538-3562</phone>
      <email>Terry.Ciara@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Aaron Krych, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruce Levy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Stuart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University/Jameson Crane Sports Medicine Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna DeFranco</last_name>
      <phone>614-293-2761</phone>
      <email>jenna.defranco@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Angela Pedroza, MPH</last_name>
      <phone>614-293-2952</phone>
      <email>angela.pedroza@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Magnussen, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Flanigan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Kaeding, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NOVOSTITCH</keyword>
  <keyword>meniscal</keyword>
  <keyword>meniscus</keyword>
  <keyword>repair</keyword>
  <keyword>knee</keyword>
  <keyword>horizontal cleavage</keyword>
  <keyword>complex tear</keyword>
  <keyword>arthroscopy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

